Clearance of ASC50 paves the way for a Phase I trial in patients with mild-to-moderate plaque psoriasis.

The FDA cleared an investigational new drug application for AVZO-1418/DB-1418, and a phase 1/2 trial in advanced solid tumors ...

Duality Biotherapeutics ("DualityBio", HKEX:09606) partner Avenzo Therapeutics, Inc. ("Avenzo"), a clinical-stage biotechnology company developing next-generation oncology therapies, today announced ...

Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic ...

The US Food and Drug Administration (FDA) has cleared Grifols' investigational new drug (IND) application to initiate a Phase ...

GenScript, a global leader in life science research tools and services support, has expanded its mRNA synthesis and ...

SHELTON, CT / ACCESS Newswire / May 22, 2025 / Dr. Anil Diwan, President of NanoViricides, Inc. (NYSE Amer.:NNVC ) (the ...

Researchers at Baylor College of Medicine and the Jan and Dan Duncan Neurological Research Institute at Texas Children’s ...

AI is changing application development by automating tasks, enhancing user experiences, and predicting market trends. It is ultimately transforming ...

of its investigational new drug application (IND) for AVZO-023 (formerly ARTS-023), a potential best-in-class, novel cyclin-dependent kinase 4 (CDK4) selective inhibitor. Avenzo has also exercised its ...

Transforming Preclinical Screening with Speed, Precision, and Scalability. Explore How This Model Organism is Shaping the Next Era of Pharmaceutical Innovation. Executive Summary & Key Findings Market ...